23 Jan Autolus Therapeutics
Posted at 17:13h
in
Christopher Vann, Chief Operating Officer
April 12 | 11:00am | BioCentriq Ballroom
London, United Kingdom
(NASDAQ GS: AUTL)
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled, and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms, and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
